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Abstract 
Objectives. The global prevalence of irritable bowel syndrome (IBS) is difficult to ascertain, 
particularly in light of the heterogeneity of published epidemiological studies. The aim was to 
conduct a systematic review, by experts from around the world, of community-based studies 
on IBS prevalence. 
Design. Searches were conducted using pre-determined search terms and eligibility criteria, 
including papers in all languages. Pooled prevalence rates were calculated by combining 
separate population survey prevalence estimates to generate an overall combined meta-
prevalence estimate. The heterogeneity of studies was assessed. 
Results. 1,451 papers were returned and 83, including 288,103 participants in 41 countries, 
met inclusion criteria. The mean prevalence among individual countries ranged from 1.1% in 
France and Iran to 35.5% in Mexico. There was significant variance in pooled regional 
prevalence rates ranging from 17.5% (95% CI: 16.9; 18.2) in Latin America, 9.6 (9.5; 9.8) in 
Asia, 7.1 (8.0; 8.3) in N. America/Europe/Australia/NZ, to 5.8 (5.6; 6.0) in the Middle East 
and Africa. There was a significant degree of heterogeneity with the percentage of residual 
variation due to heterogeneity at 99.9%. 
Conclusions. The main finding is the extent of methodological variance in the studies 
reviewed and the degree of heterogeneity among them. Based on this we concluded that 
publication of a single pooled global prevalence rate, which is easily calculated, would not be 
appropriate or contributory. Furthermore, we believe that future studies should focus on 
regional and cross-cultural differences that are more likely to shed light on pathophysiology. 
 4 
Summary box 
What is already known about this subject? 
 The prevalence of IBS has been studied extensively. 
 The methodology used to study IBS prevalence is not uniform among studies. 
 Estimates of IBS prevalence usually are reported in the range of 10-20%, but the basis 
for these estimates is not clear. 
 
What are the new findings? 
 This systematic review of IBS prevalence in population-based studies was conducted 
by a multinational group of investigators, who had facilitated access to articles 
published in multiple languages because of their familiarity with regional publications 
and languages. 
 The main finding of the study is the extent of methodological variance in the studies 
and the significant degree of heterogeneity among them. 
 There is a noteworthy lack of data from Africa, Eastern Europe, and Arab countries. 
 The predominance of women who fulfill the different diagnostic criteria for IBS is 
reaffirmed in this study. 
 
How might it impact on clinical practice in the foreseeable future? 
 The assessment of prevalence rates is important for understanding the distribution and 
burden of disease, for the evaluation of treatment modalities, to provide incentive for 
the development of new drugs, and for the allocation of healthcare resources and 
research funding.  
 The lack of reliable prevalence data is a barrier to attaining these goals. 
 The results of the study highlight the need for a global survey of IBS prevalence with 
multinational collaboration and uniform research methodology. Future studies should 
focus on regional and cross-cultural differences that are more likely to shed light on 
pathophysiology 
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Introduction 
The prevalence of irritable bowel syndrome (IBS), a common functional gastrointestinal 
disorder (FGID), has been studied extensively. Multiple methodologies have been used to 
assess the prevalence of IBS around the world. It has been investigated in convenience 
samples among workers or students or during health surveys[1] and in urban neighborhoods 
and rural areas.[2-4] Some studies have been hospital- or clinic-based,[5] while others were 
community-based. In addition, the methods of data collection have included in-person 
household interview, mail survey, telephone survey and, recently, Internet-survey. Finally, 
different diagnostic criteria have been used in these studies including the Manning criteria (in 
different studies either 2, 3, or 4 of the 6 original Manning criteria were used to diagnose 
IBS), Rome I-III, and others.[6-9] 
Determining population prevalence by self-reported symptoms through a questionnaire, in 
the absence of an established diagnostic biomarker, could lead to an inaccurate estimation of 
the actual population prevalence rate. There are differences in symptom interpretation and 
reporting patterns among different countries, geographical regions, and cultural and ethnic 
groups.[10 11] Even if the survey methodology was uniform there might be cultural and 
regional differences in perception, for example relating to pain, bloating, bowel habit, and 
other symptoms. Thus, gaining a global perspective on the prevalence of IBS remains 
difficult because of methodological heterogeneity and cultural differences in symptom 
perception and reporting. Potential confounders in multinational comparative prevalence 
studies for IBS are shown in Table 1. These issues are presented and discussed succinctly by 
Quigley et al.[12] 
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Table 1. Potential sources of methodological confounding in multinational comparative 
IBS prevalence studies 
1. Variations in diagnostic criteria 
a. Manning (Using 2, 3 or 4 out of the 6 criteria) 
b. Rome I, II, III 
2. Study population 
a. Age, gender, class 
b. Culture, ethnic group, language 
c. Select group vs. representative of general population 
i. Clinic-based 
ii. Students, workers, urban vs. rural, etc.  
3. Survey instrument 
a. Questionnaire 
b. Validation of translated questionnaires 
4. Survey method 
a. Mail 
b. Personal interview 
c. Telephone 
d. Self-administered questionnaire 
e. Internet 
5. Cultural and regional differences in symptom interpretation and reporting. 
 
Lovell and Ford reported the results of a systematic review of IBS prevalence.[13] The 
authors found a pooled global prevalence of 11.2% (95% CI, 9.8%–12.8%), with a range 
among countries from 1.1% to 45.0%.  
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The purpose of the present study was to conduct a systematic review of publications 
reporting the epidemiology and prevalence of IBS in community-based studies in as many 
languages as possible. A team of experts in the field who represent all regions of the world 
and are fluent in multiple languages conducted the review. 
Methods 
The Rome Foundation commissioned a Working Team on Cross-cultural, Multinational 
Research in the FGIDs to address issues and challenges related to global research in the 
FGIDs.[10 14] The full report of the working team can be downloaded at 
http://theromefoundation.org/committees/multinational_com.cfm, and an article summarizing 
the full report was published.[15] One of the working team’s mandates was to conduct a 
systematic review of IBS global epidemiology. The review was conducted by working team 
members representing different geographical areas, each responsible for using the study 
protocol and search parameters to identify all relevant studies in their assigned region. 
Searched databases were Medline, Embase, Web of Science, Cochrane, Latindex, Bireme, 
Sci ELO, and other databases including recent abstracts, compilations, and meeting 
procedures In cases where there were other studies cited in the paper that were not identified 
in the search, they were reviewed for eligibility. In addition, there were no language 
restrictions and the investigators were encouraged to survey publications in as many 
languages as they could, getting help from colleagues in their regions to translate when 
required. The regions covered and the responsible investigators are shown in Table 2. 
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Table 2. Delegation of responsibility for regional literature searches. 
Region Investigators/s 
US and Canada Charles Gerson and William Whitehead 
Latin America Max Schmulson 
Western Europe Pali Hungin 
Eastern Europe Dan Dumitrascu 
Japan, Korea Shin Fukudo 
China, Malaysia, Thailand, Taiwan, Hong 
Kong, Singapore, Australia, New Zealand 
Kok Ann Gwee and Chen Minhu (assisted by 
Xiao R Gong) 
India and the rest of Asia Uday Ghoshal 
Middle East, Africa Ami Sperber 
 
Search terms and eligibility criteria 
The medical literature was searched using the following sequence of terms: 
IBS OR irritable bowel syndrome OR functional bowel disorder AND epidemiology OR 
prevalence AND region OR country (e.g., Latin America OR Mexico OR Guatemala OR 
Colombia OR Argentina, et al.). 
Papers and abstracts that were identified by the search terms were considered to be eligible 
for the study and were included in the analyses in accordance with the criteria shown in Table 
3. The present paper relates only to the sub-group of studies that were conducted in the 
general population or were community-based. Thus, the full study database of extracted 
articles is larger than the selected database used in the present analysis, because it also 
contains studies that are not of general or community-based populations. 
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Table 3. Eligibility criteria for the present report 
Settings General population or community-based 
studies 
Study size (number of participants) ≥100 
Age of participants in study ≥18 
Start year for articles 1999 
Start year for abstracts 2006 
Diagnostic criteria Manning (2, 3, 4), Rome (I, II, III), others or 
not reported 
 
Study database and data extraction 
Each investigator completed the database for their region and then the individual databases 
were merged into the final study database. The data that were extracted from all papers 
included the following variables (if cited in the paper): type of paper and year of publication 
(e.g., journal articles published in 1999 and later, abstracts published from 2006 to 2013); 
country; language of study; study design (e.g., cross-sectional); study setting (e.g., urban 
community); survey instrument (e.g., Rome II questionnaire); method of data collection (e.g., 
in-person interview, mail survey, telephone survey, etc.), number of participants; females 
(%); response rate (%); mean age; mean years of education; whether the study was 
multinational/cross-cultural; IBS prevalence (%); IBS prevalence by gender; IBS-
constipation (IBS-C) (%); IBS-diarrhea (IBS-D) (%); IBS-mixed (IBS-M) (%); and IBS-
unclassified (IBS-U) (%). The earliest year of publication was chosen as 1999, the year that 
the Rome II diagnostic criteria were developed, based on our perception that epidemiological 
research in the FGIDs became more rigorous at this time and that, in general, earlier research 
was less methodologically sound than studies that began around 1999-2000. 
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The representative for each region selected all papers from their region that were included 
in the final analyses, in many cases with research assistants. All papers were also read and 
reviewed by the first author (ADS). In cases where the appropriateness of the study was 
questioned by ADS, an email exchange with the regional representative was conducted to 
clarify the issues raised. Where necessary the first author of the paper was consulted for 
clarification. The final decision on inclusion was reached by agreement between ADS and the 
regional representative and, in some cases papers were excluded from the study based on this 
joint review. 
Statistical analyses 
Descriptive analyses were performed using the SPSS software package (Version 21, 
Chicago Ill). Descriptive statistics are presented as percentages for categorical variables and 
means (SD) for continuous variables. 
To calculate pooled prevalence rates we used the appropriate method, as published by 
Yang,[16] which combines separate population survey prevalence estimates into an overall 
meta-prevalence estimate. For the purpose of pooled analyses the countries were grouped into 
a) Asia, b) North America/Europe/Australia/New Zealand (NZ), c) Latin America, and d) the 
Middle East and Africa. For further analysis of the data, we used the Stata software (Version 
13.1, Stata Corp., Texas, US). We performed a univariate meta-analysis, in which each group 
of countries contributes an estimate of a single quantity (such as IBS, gender, etc.), and 
multivariate meta-analysis, in which groups of countries (geographic regions) contribute 
estimates of more than one quantity: for example, IBS sub-group by geographic region. 
Then we modeled the effects across regions, using consistency and inconsistency models. 
To analyze variables of interest we used the univariate random-effects meta-regression model 
because, compared with a fixed-effect model, it assigns more moderate weights to each 
study, i.e., more weight to small studies and less to large ones. As a result, the confidence 
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interval about each coefficient (and slope) is wider than in the fixed-effect model and the p-
values corresponding to each coefficient and to the model as a whole are less likely to meet 
the criterion for statistical significance. This added a negative bias making statistically 
significant comparisons more robust. 
For the heterogeneity statistic, the weighted sum of squares of the residuals was used as a 
generalization of Cochran’s Q from meta-analysis to meta-regression. Following this, a test 
of the null hypothesis of no residual (unexplained) heterogeneity was obtained by comparing 
Cochran’s Q to a χ2 distribution.[17 18]  
Results 
Studies included in the paper (Fig. 1) 
In all, 1,451 papers were returned by the search. Of these 162 met the inclusion criteria 
and the remaining 1,289 were disqualified for the following reasons: non-epidemiological or 
non-IBS study – 737; review – 236; duplicate (more than one report for same study) – 240; 
earlier than 1999 for article – 33; earlier than 2006 for abstract – 4; inappropriate population 
age – 23; inappropriate study design – 15; study population less than 100 – 1.  
Of the 162 publications that met the systematic review criteria 83 were included in the 
present report.[2 6 9 19-98] The other 79 were disqualified after further review because they 
were not population or community based or they were repeat publications of the same data. 
Of the 83 studies included in this review, 41 were published in the English-language 
literature. The others were distributed as follows: Spanish - 16, Chinese - 13, Persian - 3, 
Turkish - 2, Arabic, Dutch, Finnish, Greek, Hebrew, Icelandic, Norwegian, and Portuguese - 
1 each. 
The final 83 studies included 288,103 participants in 41 countries (the largest study 
encompassed eight countries). The mean number of participants per study was 3,471.1 and 
the median sample size was 1,624.0. The largest numbers of studies, by country, were from 
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China (N=8), Japan (N=6), and South Korea and Mexico (N=5 each). The mean pooled 
response rate, reported in 62 studies, was 71.3% (95% CI: 71.1; 71.4). The response rates by 
region were 89.0% in Asia (N=19), 85.3% in Latin America (N=16), 76.5% in the Middle 
East and Africa (N=11) and 54.0% in North America/ Europe/Australia/New Zealand 
(N=19). 
In 77 papers (92.8%) the authors reported the method of data collection including personal 
interview (N=40 [51.9%]), mail (N=16 [20.8%]), and telephone (N=9 [11.7%]). Personal 
interviews were the method of data collection in 16 of 21 studies from Asia (76.2%), 9 of 12 
studies (75%) from the Middle East, 9 of 12 studies (75%) from Africa, and 8 of 14 studies 
(57.1%) from Latin America. Personal interviews were less commonly employed in North 
America/ Europe/Australia/New Zealand (7 of 23, 30.4%) with more studies using mailed 
questionnaires (13 of 23, 56.0%) and some using telephone interviews (3 of 23, 13.0%). IBS 
prevalence by survey method was 6.8% by personal interview, 10.5% by mail questionnaire, 
and 8.0% by telephone interview for all regions taken together. 
Diagnostic criteria 
Twelve studies used the Manning criteria (7 as a single criterion), 12 used Rome I (7 as a 
single criterion), 38 Rome II (36 as a single criterion), 14 Rome III (12 as a single criterion), 
and seven used other criteria. IBS prevalence by diagnostic criteria was 7.8% by Rome II 
(N=38), 8.3% by Manning criteria, 6.7% by Rome I, 9.1% by Rome III, and 12.8% in studies 
in which the diagnostic criterion was not specified. Table 4 presents regional IBS prevalence 
rates by method of data collection and diagnostic criteria. 
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Table 4. Comparison of regional pooled prevalence rates (%) for IBS by sex, survey 
method, and diagnostic criteria. 
 
Latin 
America 
US/Europe/ 
Australia/NZ 
Asia 
Middle 
East 
Sex 
 Male 
 Female 
 
12.5 
20.5 
 
6.1 
10.4 
 
8.4 
10.4 
 
4.6 
6.2 
Survey method 
 Mail questionnaire 
 Personal interview 
 Telephone 
 
20.0 (N=5) 
12.5 (N=8) 
24.7 (N=1) 
 
8.9 (N=13) 
6.9 (N=7) 
7.9 (N=3) 
 
11.9 (N=3) 
7.6 (N=16) 
4.8 (N=2) 
 
0 
4.7 (N=9) 
6.2 (N=3) 
Diagnostic criteria 
 Manning 
 Rome I 
 Rome II 
 Rome III 
 Other 
 
24.8 (N=2) 
0 
20.4 (N=8) 
15.2 (N=5) 
12.5 (N=2) 
 
8.1 (N=8) 
6.8 (N=7) 
7.9 (N=7) 
29.2 (N=1) 
12.9 (N=2) 
 
 
7.0 (N=2) 
6.6 (N=5) 
5.7 (N=10) 
12.9 (N=6) 
12.9 (N=2) 
 
0 
0 
9.0 (N=13) 
1.5 (N=2) 
0 
 
Sociodemographic variables 
Of the 288,103 participants 55.0% (95% CI: 46.2; 69.4) were females (N=74 studies) with 
a range from 28% [96] to 74.3% [31]. The mean age was 40.0 (95% CI: 31.2; 51.0) years 
with a range from 27.7 years (Vietnam),[51] to 53.0 years (Germany).[57] 
Prevalence rates 
Individual study rates 
The 83 studies were conducted in 41 countries. The mean IBS prevalence by country 
ranged from 3.3% in France (N=3 studies) to 31.6% in Nigeria (N=1 study). There was a 
significant difference in the mean prevalence among countries (P<0.0001). The prevalence, 
in individual studies, ranged from 1.1% in France[71] and Iran[94] to 35.5% in Mexico.[97] 
Different studies from the same country yielded, in some cases, a broad range of results. For 
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example in the five studies included in this paper from Mexico the prevalence rates were: 
4.4%,[86] 16.0%,[84] 16.9%,[81] 28.9%,[85] and 35.5%.[97] 
Forty two studies reported prevalence rates for IBS sub-groups (IBS-D, IBC-C, etc.). 
There was a difference in the prevalence of IBS-C among the regions, ranging from 12.7% 
for Asia, 13.6% for North America/Western Europe/Australia/NZ, 39.4% for Latin America, 
to 43.3% for the Middle East. The data were not sufficient to make other analyses of IBS by 
sub-type. 
Pooled rates 
Table 5 shows the pooled prevalence rate for IBS per region. Pooled prevalence rates were 
higher in women than men (10.2% vs. 8.8%), and prevalence rates were also higher in 
women than men in each region separately (Table 5). 
Table 5. IBS prevalence, gender, and age, by geographical region.* 
Region 
Studies 
N 
Subjects 
N 
Prevalence 
% (95% CI) 
(N=83) 
Gender 
% female (95% CI) 
(N=74) 
Age 
Mean (95% CI) 
(N=53) 
Asia 25 114,474 9.6 (9.5; 9.8) 51.3 (43.5; 59.0) 39.6 (27.7; 52.5) 
N. America/Europe/ 
Australia/NZ 
26 116,752 8.1 (7.0; 8.3) 56.3 (51.0; 71.0) 43.3 (31.5; 53.0) 
Latin America 17 12,805 17.5 (16.9; 18.2) 59.4 (28.0; 69.4) 37.5 (29.4; 47.7) 
Middle East/Africa 15 44,072 5.8 (5.5; 6.0) 55.7 (50.0; 71.6) 40.5 (32.3; 49.9) 
All 83 288,103 8.8 (8.7; 8.9) 55.0 (46.2; 69.4) 40.0 (31.2; 51.0) 
*Prevalence = pooled prevalence; gender and age are unadjusted for sample size within 
regions.  
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The highest prevalence rate was found in Latin America at 17.5% (95% CI: 16.9; 18.2). 
Although there were many studies conducted in Latin America (N=17, 20.5% of all studies), the 
total number of participants in that region was low (N=12,805, 4.4% of all subjects). Thus, the 
studies in that region had substantially lower sample sizes than other regions of the world, with a 
mean in Latin America of 753, compared to 4,491 for North America, Western Europe, 
Australia/New Zealand, 3,999 for Asia, and 3,844 for the Middle East. 
There was a statistically significant degree of heterogeneity among the geographical regions, 
using North America/Europe/ Australia/NZ (Table 6) as the reference region and confirmed 
using Latin America as the reference group (not shown) in two separate runs. The results of the 
univariate random-effects meta-regression for IBS by region appear in Table 6. 
Table 6. Univariate random-effects meta-regression for IBS, by region with North  
America/ Europe/Australia/NZ as the reference group. 
% Residual variation due to heterogeneity - 99.9% 
Proportion of between-study variation explained - 24.0% 
Region 
Pooled 
prevalence 
Coefficient SE P 95% CI 
Latin America 19.24 7.19 2.17 0.001 2.86; 11.52 
Asia 8.14 -3.92 1.84 0.036 -7.58; -0.26 
Middle East 10.53 -1.52 2.68 0.571 -6.85; 3.81 
Constant (North 
America et al.) 
12.05 12.86 7.45 1.000 -2.25; 27.96 
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Discussion 
We conducted a systematic review of IBS prevalence in 83 general population or community-
based studies conducted around the world and reported in multiple languages. We believe that 
the most significant finding of the present study is the extent of methodological variance in the 
included studies and the statistically significant degree of heterogeneity among them, not the 
calculated pooled global IBS prevalence or even the prevalence by geographical region. This 
result should not be surprising in light of the variation in sample size, setting, diagnostic criteria, 
method of data collection, and overall research methodology.[99] In fact, our results show very 
heterogeneous results when comparing IBS prevalence rates by regions and potential 
confounding factor, e.g., method of data collection and diagnostic criteria used (Table 5). 
Compounding these factors are potential cultural differences in the reporting and 
interpretation of symptoms[15] and the effect of inappropriate translation of study 
questionnaires.[100 101] 
In this respect our results are compatible with those reported by Lovell and Ford[13] since 
they also found significant heterogeneity between studies in all of their statistical analyses, 
although they placed less emphasis on this finding. The review by Lovell and Ford included 80 
articles, while the present study includes 83. Thus, the question might arise as to why the present 
study did not contain a much larger number of papers since it has more foreign language articles 
and could include articles published after the Lovell and Ford paper. We believe that there are 
several explanations for this outcome: a) the time frame for the Lovell and Ford review was 
1947-2011, while the time frame for the present study was much shorter from 1999-2013, b) the 
Lovell and Ford review included studies with subjects from the age of 15 and above while the 
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present one included studies with subjects from the age of 18 and above and c) the lower limit 
for the number of study subjects in the Lovell and Ford review was 50, while the lower limit in 
the present study was 100.  
Prevalence rates are important for multiple reasons including: a) for epidemiologists and 
health economists - the distribution and burden of disease; b) for clinicians - commonality of 
disease, probability of diagnosis and evaluation of treatment modalities; c) for the 
pharmaceutical industry and regulators - incentive to develop new drugs; d) for health policy 
makers - allocation of healthcare resources and research funding; e) for clinicians, 
epidemiologists, medical anthropologists et al. - cross-cultural comparisons, and f) for all - the 
satisfaction of intellectual and scientific curiosity. 
There is a noteworthy lack of data from certain areas of the world. The African continent is 
almost completely unrepresented and most studies conducted there[5 102] were on select 
populations, which disqualified them from inclusion in the present systematic review. Other 
regions that were seriously underrepresented are Eastern Europe and the Arab world. 
Surprisingly there were only two studies[31 32] from the United States and Canada that were 
considered to meet the study inclusion criteria. We believe this is a consequence of a shift in 
emphasis from overall prevalence of IBS in the population to the association of IBS diagnosis 
with other characteristics such as age, race, ethnicity, and socioeconomic status. Also the 
absence of a centralized health care system could limit epidemiological studies in the US. 
Despite the heterogeneity of results, which makes it difficult to assess the global prevalence of 
IBS, it is clearly a prevalent disorder. The Lovell and Ford review is a landmark report on global 
IBS prevalence. Nevertheless, we believe that the results of the present study had an advantage 
in that it accessed more bibliographic depositories including languages other than English and 
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had a large group of expert investigators who reviewed the literature in their own regions with 
expert translation at hand when needed. In fact, judging by its list of references, the Lovell and 
Ford study had less than half the number of articles that were published in a language other than 
English, compared to the present study, particularly in Spanish and Chinese. One of their 
conclusions was that there is a scant amount of published data from Central America (e.g., 
Mexico). We have included several relevant studies from that region. Thus, the two systematic 
reviews can be viewed as complementary, and similar conclusions can be drawn from them, 
especially relating to the heterogeneity of methodologies used in epidemiological studies of IBS, 
with the inherent implications for the interpretation of prevalence comparisons. 
Another finding that is consistent throughout the studies is the predominance of females. 
Some individual studies, for example from India, have shown higher rates among men than 
women. These studies are usually from a clinical setting and may reflect higher consulter rates 
among men than women in certain cultures.[103-105] Although the prevalence of IBS among 
men is lower than women it is still high in absolute terms, justifying and even mandating the 
inclusion of men in clinical trials. 
The main strengths of this study include the rigorous design and search parameters, the 
exclusion of non-population-based and non-community studies, the composition of the expert 
team that reviewed all the papers by region, and the inclusion of many non-English language 
papers, articles published in journals not included in major repositories, and recent abstracts. The 
meta-regression analysis assured a pooled prevalence that combines separate population survey 
prevalence estimates to generate an overall combined estimate. The results of the heterogeneity 
analyses made it clear that we cannot infer that the overall pooled prevalence is a reliable 
statistic. Thus, the heterogeneity of the results precludes firm conclusions as to the global 
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prevalence of IBS. However, we do not regard this as a study limitation; Rather, it is a clear 
outcome of the study, which can drive future research. 
A potential limitation of this study is that we did not have a formal requirement that the data 
search and extraction be conducted in duplicate. However, there were several safeguards in 
place. No article was accepted as eligible for review unless both the regional PI and the study PI 
(ADS) approved it. As mentioned above, in all cases of doubt the paper’s eligibility was 
determined by joint review and, in some cases, papers originally considered eligible for the study 
were rejected. In addition, although duplicate searches were not mandated, in practice in most 
regions there was more than one investigator who determined the eligibility of the papers that 
they extracted and this was followed by the overall review of eligibility by the first author. 
Other potential limitations include insufficient or absent data from some areas of the world. 
Again, since this reflects the actual situation it is less a limitation than an outcome of the study. 
The allocation of regions for data analyses could be somewhat problematic in that some regions 
may be more heterogeneous than others. An alternative approach that might reduce heterogeneity 
could be to assess IBS prevalence in pooled studies by diagnostic criteria or method of data 
collection, which we did in secondary analyses. However, many papers used more than one 
diagnostic criterion in the same study and some did not use the more established criteria at all, so 
this approach also has inherent difficulties. Another strategy could be to define smaller 
geographical regions, for example to divide Asia and/or Latin America into smaller, more 
homogeneous sub-regions. However, the number of regions for analysis would increase and the 
N for each region would become small, in some cases to the point of obviating useful analyses. 
Decisions of this type always entail a trade-off and the final decision is always likely to engender 
criticism. 
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In conclusion, given current methodological limitations, the goal of ascertaining a globally 
representative prevalence rate for IBS is likely to elude researchers for some time. However, this 
might actually be less important than determining reliable regional estimates of IBS prevalence 
and comparing these differences among regions in terms of variables such as diet, exposure to 
pathogens, health care practices, psychological variables, and prevailing cultural and religious 
beliefs. Studies with this more limited goal may advance our understanding of the 
pathophysiology of IBS and improve its medical management more effectively than a global 
estimate of IBS prevalence. 
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Fig. 1. Flow diagram of citations retrieved by the literature search and included in the present 
study.  
  
